Top Biotech & Pharma Acquisitions
Read the deals. Read the strategy.
A live view of the most consequential biotech and pharma acquisitions — by deal value, strategic intent and pricing benchmarks.
"What are recent acquisitions telling us about where pharma capital is moving?"
Recent deal flow concentrates in oncology (ADCs, bispecifics), rare disease, and metabolic-cardio. Bolt-on $1–10B dominates; mega-deals rare.
The most consequential biotech and pharma acquisitions follow patent-cliff defense, ADC consolidation, and metabolic-cardio resurgence. Reading deals as a system — acquirer pattern × hot-zone × multiple — beats reading them as headlines.
What we’re seeing in the data.
ADC consolidation is a defining wave
Multiple $20B+ ADC-led deals in 24 months.
Rare disease premiums hold up
Specialized rare-disease portfolios price 10–15× revenue.
Bolt-on > mega-deal pattern
Antitrust + integration risk push toward focused buys.
How to think about it.
-
01
Track deal flow live
Cortellis / Capital IQ.
-
02
Score by hot-zone
TA × stage × multiple.
-
03
Identify acquirer pattern
Cliff / platform / bolt-on.
-
04
Predict next moves
Cliff exposure × pipeline gap.
What separates a good answer from a defensible one.
FTC scrutiny rising.
Recent M&A absorbs bandwidth.
Sets deal floor.
Where the signal comes from.
Common questions.
Why mostly bolt-ons?
Antitrust + targeted pipeline-cliff fixes favor focused deals.
Refresh cadence?
Live for deal flow; weekly synthesis.
Want this answered on your data?
We build decision systems on top of analyses like this — so the next question takes minutes, not weeks.
Talk to a strategist